Nifty
:
24286.50
Sensex
:
79986.80
162.65 (0.67%)
545.35 (0.69%)
Nifty
Sensex
:
:
24286.50
79986.80
162.65 (0.67%)
545.35 (0.69%)

Solara Active Pharma Sciences Ltd.

Pharmaceuticals & Drugs - API

Rating :
43/99

BSE: 541540 | NSE: SOLARA

NSE BSE
570.00
03-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  587.70
  •  587.70
  •  556.35
  •  585.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  380491
  •  2153.85
  •  597.35
  •  263.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,810.40
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,801.18
  • N/A
  • 2.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.49%
  • 16.85%
  • 20.15%
  • FII
  • DII
  • Others
  • 15.8%
  • 1.71%
  • 15.00%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 0.50
  • -3.70

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -8.74
  • -19.08

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 10.48
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.75
  • 1.47

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 7.29
  • 5.29

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
299.43
380.62
-21.33%
248.73
394.75
-36.99%
425.24
338.37
25.67%
352.31
330.07
6.74%
Expenses
289.67
331.86
-12.71%
410.42
349.75
17.35%
387.61
310.80
24.71%
333.19
317.52
4.94%
EBITDA
9.76
48.76
-79.98%
-161.69
45.00
-
37.63
27.57
36.49%
19.12
12.55
52.35%
EBIDTM
3.26%
12.81%
-65.01%
11.40%
8.85%
8.15%
5.43%
3.80%
Other Income
1.70
4.68
-63.68%
0.45
7.17
-93.72%
1.18
3.72
-68.28%
2.04
6.98
-70.77%
Interest
30.69
21.96
39.75%
25.37
23.64
7.32%
24.44
21.96
11.29%
24.61
22.50
9.38%
Depreciation
25.25
26.45
-4.54%
25.96
27.98
-7.22%
26.21
28.63
-8.45%
25.91
28.13
-7.89%
PBT
-166.66
5.03
-
-275.34
0.55
-
-17.06
-19.30
-
-29.36
-31.10
-
Tax
88.79
1.28
6,836.72%
0.00
0.12
-100.00%
0.00
-9.32
-
-10.25
-14.65
-
PAT
-255.45
3.75
-
-275.34
0.43
-
-17.06
-9.98
-
-19.11
-16.45
-
PATM
-85.31%
0.99%
-110.70%
0.11%
-4.01%
-2.95%
-5.42%
-4.98%
EPS
-65.37
0.96
-
-70.49
0.12
-
-4.39
-2.55
-
-5.00
-4.21
-

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Net Sales
1,325.71
1,443.81
1,268.35
1,616.88
1,321.75
1,408.58
560.41
Net Sales Growth
-8.18%
13.83%
-21.56%
22.33%
-6.16%
151.35%
 
Cost Of Goods Sold
805.02
788.83
653.89
724.42
598.87
724.03
293.38
Gross Profit
520.69
654.98
614.46
892.46
722.88
684.55
267.03
GP Margin
39.28%
45.36%
48.45%
55.20%
54.69%
48.60%
47.65%
Total Expenditure
1,420.89
1,309.93
1,188.38
1,231.01
1,062.31
1,197.03
500.80
Power & Fuel Cost
-
108.10
93.70
85.42
77.68
79.35
31.41
% Of Sales
-
7.49%
7.39%
5.28%
5.88%
5.63%
5.60%
Employee Cost
-
228.63
236.34
229.37
204.13
187.82
71.51
% Of Sales
-
15.84%
18.63%
14.19%
15.44%
13.33%
12.76%
Manufacturing Exp.
-
91.64
100.60
95.82
94.74
101.85
48.02
% Of Sales
-
6.35%
7.93%
5.93%
7.17%
7.23%
8.57%
General & Admin Exp.
-
39.43
49.31
47.86
47.70
35.50
15.22
% Of Sales
-
2.73%
3.89%
2.96%
3.61%
2.52%
2.72%
Selling & Distn. Exp.
-
31.68
30.28
31.88
24.70
31.33
17.84
% Of Sales
-
2.19%
2.39%
1.97%
1.87%
2.22%
3.18%
Miscellaneous Exp.
-
21.62
24.26
16.24
14.49
37.15
23.42
% Of Sales
-
1.50%
1.91%
1.00%
1.10%
2.64%
4.18%
EBITDA
-95.18
133.88
79.97
385.87
259.44
211.55
59.61
EBITDA Margin
-7.18%
9.27%
6.31%
23.87%
19.63%
15.02%
10.64%
Other Income
5.37
22.55
20.02
28.77
27.52
12.38
2.47
Interest
105.11
90.06
75.28
84.48
77.89
82.48
25.17
Depreciation
103.33
111.19
112.32
108.66
94.16
83.70
36.71
PBT
-488.42
-44.82
-87.61
221.50
114.91
57.75
0.20
Tax
78.54
-22.57
-32.81
0.15
0.39
-1.66
-0.14
Tax Rate
-16.08%
50.36%
36.02%
0.07%
0.34%
-2.87%
-70.00%
PAT
-566.96
-22.18
-58.15
221.40
114.61
59.51
0.38
PAT before Minority Interest
-567.39
-22.25
-58.29
221.35
114.52
59.41
0.34
Minority Interest
-0.43
0.07
0.14
0.05
0.09
0.10
0.04
PAT Margin
-42.77%
-1.54%
-4.58%
13.69%
8.67%
4.22%
0.07%
PAT Growth
0.00%
-
-
93.18%
92.59%
15,560.53%
 
EPS
-157.49
-6.16
-16.15
61.50
31.84
16.53
0.11

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Shareholder's Funds
1,500.21
1,524.87
1,588.53
1,085.94
955.87
763.98
Share Capital
36.00
36.00
35.93
26.85
25.77
24.67
Total Reserves
1,463.16
1,487.87
1,548.81
958.36
823.71
739.30
Non-Current Liabilities
217.14
299.22
206.46
333.31
344.23
315.06
Secured Loans
235.10
283.04
154.83
232.71
224.97
242.86
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
49.03
37.07
36.56
32.62
28.79
23.58
Current Liabilities
1,101.13
1,063.42
788.74
729.89
655.50
737.95
Trade Payables
305.86
275.99
309.29
216.12
244.38
312.87
Other Current Liabilities
144.38
173.76
116.60
157.28
192.24
90.08
Short Term Borrowings
648.80
609.90
360.88
353.79
214.47
330.21
Short Term Provisions
2.09
3.77
1.97
2.70
4.41
4.78
Total Liabilities
2,820.72
2,889.82
2,587.97
2,153.43
1,959.98
1,821.47
Net Block
1,340.02
1,331.80
1,381.58
1,396.94
1,217.80
1,085.93
Gross Block
1,867.65
1,760.45
1,702.15
1,611.23
1,339.37
1,122.64
Accumulated Depreciation
527.63
428.65
320.57
214.29
121.57
36.71
Non Current Assets
1,633.18
1,650.54
1,530.34
1,481.44
1,311.88
1,213.66
Capital Work in Progress
238.47
238.65
87.98
40.47
40.37
71.48
Non Current Investment
1.70
0.42
0.42
0.32
0.41
0.81
Long Term Loans & Adv.
28.54
54.60
59.19
40.83
36.23
46.40
Other Non Current Assets
0.51
0.48
1.17
2.88
17.07
9.03
Current Assets
1,187.54
1,239.28
1,057.63
671.99
648.10
607.81
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
558.09
575.55
294.97
279.73
213.94
187.66
Sundry Debtors
536.99
489.67
483.87
226.53
288.80
262.52
Cash & Bank
8.89
47.25
198.54
56.78
76.47
47.01
Other Current Assets
83.57
17.94
72.93
39.87
68.89
110.62
Short Term Loans & Adv.
60.35
108.87
7.32
69.08
19.76
35.14
Net Current Assets
86.41
175.86
268.89
-57.90
-7.40
-130.14
Total Assets
2,820.72
2,889.82
2,587.97
2,153.43
1,959.98
1,821.47

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Cash From Operating Activity
156.25
-242.03
155.46
242.15
166.33
49.22
PBT
-44.82
-91.10
221.50
114.91
57.75
0.20
Adjustment
186.79
180.96
173.16
168.03
148.26
62.76
Changes in Working Capital
0.74
-313.79
-205.84
-16.45
-25.29
-10.84
Cash after chg. in Working capital
142.71
-223.93
188.82
266.49
180.72
52.11
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
13.54
-18.10
-33.36
-24.34
-14.39
-2.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-81.14
-242.85
-106.30
-358.81
-115.69
-85.47
Net Fixed Assets
-107.02
-226.06
-138.36
-272.61
-185.65
Net Investments
-1.28
3.36
-0.10
0.09
0.41
Others
27.16
-20.15
32.16
-86.29
69.55
Cash from Financing Activity
-112.76
333.57
92.49
96.98
-23.39
67.74
Net Cash Inflow / Outflow
-37.65
-151.31
141.65
-19.68
27.25
31.49
Opening Cash & Equivalents
46.38
197.69
56.04
75.72
45.95
0.00
Closing Cash & Equivalent
8.73
46.38
197.69
56.04
75.72
45.95

Financial Ratios

Standalone /

Consolidated
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
383.80
423.30
441.06
366.93
329.64
309.63
ROA
-0.78%
-2.13%
9.34%
5.57%
3.14%
0.02%
ROE
-1.47%
-3.75%
17.23%
12.48%
7.36%
0.04%
ROCE
1.79%
-0.67%
15.34%
11.73%
9.70%
1.82%
Fixed Asset Turnover
0.80
0.73
0.98
0.90
1.14
0.50
Receivable days
129.77
140.08
80.18
71.15
71.43
170.98
Inventory Days
143.29
125.26
64.87
68.16
52.03
122.23
Payable days
134.61
163.35
132.36
75.74
84.47
228.45
Cash Conversion Cycle
138.45
101.99
12.69
63.58
39.00
64.76
Total Debt/Equity
0.67
0.67
0.38
0.72
0.63
0.83
Interest Cover
0.50
-0.21
3.62
2.48
1.70
1.01

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019

News Update:


  • Solara Active Pharma - Quarterly Results
    29th May 2024, 15:36 PM

    Read More
  • USFDA inspects Solara Active Pharma Sciences’ Visakhapatnam Facility
    20th May 2024, 11:50 AM

    The Agency with their designated investigator inspected the facility from May 14 to 17, 2024

    Read More
  • Solara Active Pharma Sciences sells 100% stake in SeQuent Penems
    26th Apr 2024, 09:46 AM

    Hence, SeQuent Penems ceased to be a subsidiary of the Company

    Read More
  • Solara Active Pharma Sciences gets nod to sell 100% stake in SeQuent Penems
    26th Mar 2024, 09:49 AM

    The board of directors of the company at its meeting held on March 25, 2024 approved the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.